Lupus Research Alliance News
Great News for Lupus Nephritis Treatment: Itolizumab Fast-Tracked by FDA

December 10, 2019 The Lupus Research Alliance (LRA) is pleased to share that a potential new treatment in development by Equillium, Inc. for lupus nephritis, itolizumab, was granted Fast Track designation by the U.S. Food and Drug Administration.  As defined by the FDA, this designation is “designed to facilitate the development, and expedite the review […] READ MORE

Lupus Research Alliance Applauds Phase III Trial Results for Potential Lupus Nephritis Treatment

December 4, 2019 The Lupus Research Alliance congratulates Aurinia Pharmaceuticals on achieving the first positive Phase III trial results for an urgently needed treatment for lupus nephritis. The company’s investigational drug voclosporin showed positive effectiveness and good safety for treating lupus nephritis in combination with standard therapy. “Lupus nephritis is one of the most common […] READ MORE

Positive Study Results in Potential Treatment for Cutaneous and Systemic Lupus

December 3, 2019 The Lupus Research Alliance (LRA) is pleased to share positive results reported by Biogen Inc. from the Phase 2 LILAC study which tested the effectiveness and safety of a potential lupus treatment, BIIB059. BIIB059 is a monoclonal antibody that targets BDCA2, a protein found on cells known as plasmacytoid dendritic cells, which […] READ MORE

LRA Researchers Star at ACR/ARP – Part 2

Last week we gave you only half the story of what scientists funded by the Lupus Research Alliance (LRA) shared at 2019 ACR/ARP. So many studies were presented that we needed to bring you Part 2 to expand our coverage of the major discoveries your donations have made possible. And a Part 3 is yet […] READ MORE

The Lupus Research Alliance Partners with the National Kidney Foundation to Offer Course to Healthcare Professionals

November 12, 2019 The Lupus Research Alliance (LRA) is pleased to announce a new collaboration with the National Kidney Foundation (NKF) on a free course for healthcare professionals about ways to better diagnose, monitor and treat patients with systemic lupus erythematosus (SLE) and lupus nephritis. The online course is critically important because as the community […] READ MORE

LRA-Funded Scientists Command Attention at 2019 ACR/ARP

November 14, 2019 The Lupus Research Alliance was proud of the unprecedented number of the studies supported by the Alliance chosen for presentation at the 2019 ACR/ARP Annual Meeting, the world’s largest rheumatology conference. A total of 19 studies were shared in oral presentations to large audiences, while 13 were presented as posters, which allow […] READ MORE

Two Lupus Therapeutics Studies Report Positive Results at 2019 ACR/ARP Annual Meeting

November 12, 2019 Two positive clinical studies presented at the 2019 ACR/ARP Annual Meeting were conducted through the Lupus Clinical Investigators Network (LuCIN) formed and managed by Lupus Therapeutics, an affiliate of the Lupus Research Alliance. Results of both studies hold promise to improve how physicians can better monitor lupus patients’ symptoms and disease activity. […] READ MORE

Potential Lupus Nephritis Treatment Works Well with Mycophenolate Acid

November 8, 2019 Aurinia Pharmaceuticals announced results from a study showing that their investigational drug voclosporin did not significantly impact the levels of mychophenolate acid (MPA), the main ingredient  in the common standard treatment mycophenolate mofetil (CellCept®) for lupus nephritis. The drug-drug interaction (DDI) study was requested by the Food and Drug Administration to measure […] READ MORE

Lupus Research Alliance Response to Positive Data from Phase 3 Anifrolumab Trial Presented at 2019 ACR/ARP Annual Meeting

NEW YORK, NY – November 11. The Lupus Research Alliance (LRA) congratulates AstraZeneca on new positive results from the Phase 3 TULIP-2 trial (Treatment of Uncontrolled Lupus via the Interferon Pathway) presented at the 2019 ACR/ARP Annual Meeting.  The data showed that the investigational biologic treatment anifrolumab significantly reduced disease activity for people with lupus. […] READ MORE

Learn and connect with our community!